- Home
- OMER vs UMAC Comparison
OMER vs UMAC Comparison
Compare OMER & UMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | OMER | UMAC |
|---|---|---|
| Founded | 1994 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | 2008 | 2023 |
Fundamental Metrics
Financial Performance| Metric | OMER | UMAC |
|---|---|---|
| Price | $18.37 | $15.29 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 9 |
| Target Price | $27.50 | ★ $35.89 |
| AVG Volume (30 Days) | 1.0M | ★ 2.5M |
| Earning Date | 11-12-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 98.15 | 80.73 |
| EPS | ★ 0.77 | 0.06 |
| Revenue | ★ $29,868,000.00 | $11,199,217.00 |
| Revenue This Year | N/A | $406.76 |
| Revenue Next Year | $73.59 | $98.42 |
| P/E Ratio | ★ $24.20 | $287.75 |
| Revenue Growth | N/A | ★ 101.23 |
| 52 Week Low | $6.24 | $7.25 |
| 52 Week High | $21.24 | $34.93 |
Technical Indicators
Market Signals| Indicator | OMER | UMAC |
|---|---|---|
| Relative Strength Index (RSI) | 52.83 | 31.99 |
| Support Level | $18.01 | $13.06 |
| Resistance Level | $19.81 | $17.14 |
| Average True Range (ATR) | 0.91 | 1.38 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 63.02 | 9.62 |
Price Performance
Historical ComparisonAbout OMER Omeros Corporation
Omeros Corp is an inventive, commercial-stage biotechnology company that discovers and develops first-in-class protein and small-molecule therapeutics for large-market and orphan indications, with particular emphasis on complement-mediated diseases, cancers, and addictive or compulsive disorders. The company's clinical-stage development programs include: narsoplimab, its antibody targeting mannan-binding lectin-associated serine protease 2 (MASP-2), the effector enzyme of the lectin pathway of complement; OMS1029, its long-acting antibody targeting MASP-2; and OMS527, its phosphodiesterase 7 (PDE7) inhibitor program.
About UMAC Unusual Machines Inc.
Unusual Machines Inc is engaged in manufactures and sells drone components and drones across a diversified brand portfolio through business-to-business (B2B) sales and a curated retail channel.